Article
Multidisciplinary Sciences
Jun Hee Lim, James Q. Wang, Fiona Webb, Kartik Saxena, Daniel Enosi Tuipulotu, Abhimanu Pandey, Si Ming Man, Dipti Talaulikar
Summary: Waldenstrom macroglobulinemia (WM) is characterized by the presence of a specific mutation in both malignant plasma cells (PCs) and lymphoplasmacytic cells (LPCs), and the expression of the same auto-reactive IgHV sequences in both cell types. Malignant PCs are primarily responsible for the secretion of IgM, and targeting these cells may be beneficial in the treatment of WM.
Article
Oncology
Steven P. Treon, Kirsten Meid, Joshua Gustine, Guang Yang, Lian Xu, Xia Liu, Christopher J. Patterson, Zachary R. Hunter, Andrew R. Branagan, Jacob P. Laubach, Irene M. Ghobrial, M. Lia Palomba, Ranjana Advani, Jorge J. Castillo
Summary: In this study, the long-term and final analysis of ibrutinib monotherapy in previously treated patients with WM showed promising results in disease control. Response to treatment was impacted by mutation status of MYD88 and CXCR4, with MYD88(Mut)CXCR4(WT) patients demonstrating higher progression-free survival rates. Treatment with ibrutinib was well-tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Hematology
Jorge J. Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P. Treon
Summary: BTK inhibitors play a crucial role in the treatment of Waldenstrom macroglobulinemia, being the only FDA-approved agents for these patients. However, there are still unmet needs with BTK inhibitor therapy, such as indefinite duration therapy, high cost, scarcity of complete responses, and lower response rates in patients with CXCR4 mutations. This review focuses on the data supporting the use of covalent BTK inhibitors, management issues, clinical trials with covalent BTK inhibitor combination regimens, and upcoming non-covalent BTK inhibitors.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Antonio Sacco, Vanessa Desantis, Jon Celay, Viviana Giustini, Fabio Rigali, Francesco D. Savino, Michele Cea, Debora Soncini, Antonia Cagnetta, Antonio G. Solimando, Deborah D'Aliberti, Silvia Spinelli, Daniele Ramazzotti, Camillo Almici, Katia Todoerti, Antonino Neri, Antonella Anastasia, Alessandra Tucci, Marina Motta, Marco Chiarini, Yawara Kawano, Jose A. Martinez-Climent, Rocco Piazza, Aldo M. Roccaro
Summary: Recent investigations have shown that Waldenstrom macroglobulinemia (WM) exhibits an increased number of regulatory T cells (Tregs), and Tregs derived from patients with WM have a peculiar mRNA signature and functional phenotype. WM cells trigger significantly higher induction, expansion, and proliferation of Tregs compared to normal cells, especially in the context of CXCR4(C1013G)-mutated WM cells. CD40/CD40-ligand interaction is identified as an important axis supporting the interaction between WM cells and Tregs.
Article
Hematology
Steven P. Treon, Kirsten Meid, Zachary R. Hunter, Catherine A. Flynn, Shayna R. Sarosiek, Carly R. Leventoff, Timothy P. White, Yang Cao, Aldo M. Roccaro, Antonio Sacco, Maria G. Demos, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Lian Xu, Christopher J. Patterson, Manit Munshi, Nicholas Tsakmaklis, Guang Yang, Irene M. Ghobrial, Andrew R. Branagan, Jorge J. Castillo
Summary: The study examined the combination of CXCR4-antagonist ulocuplumab and ibrutinib in treating WM patients, demonstrating promising clinical efficacy and survival outcomes.
Review
Oncology
Shayna Sarosiek, Steven P. Treon, Jorge J. Castillo
Summary: There are multiple treatment options available for Waldenstrom macroglobulinemia patients, including chemotherapy, monoclonal antibodies, proteasome inhibitors, and covalent Bruton tyrosine kinase (BTK) inhibitors. Treatment decisions should be personalized based on the patient's clinical presentation, genetic profile, and treatment preferences. While ibrutinib monotherapy is favored in certain genetic subtypes, other options like chemoimmunotherapy or proteasome inhibitor-based regimens should also be considered.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Jorge J. Castillo, John N. Allan, Tanya Siddiqi, Ranjana H. Advani, Kirsten Meid, Carly Leventoff, Timothy P. White, Catherine A. Flynn, Shayna Sarosiek, Andrew R. Branagan, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Christopher J. Patterson, Zachary R. Hunter, Matthew S. Davids, Richard R. Furman, Steven P. Treon
Summary: Venetoclax demonstrates safety and efficacy in previously treated WM patients, including those who previously received BTKis. CXCR4 mutation status does not affect treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Maaya Awata-Shiraiwa, Akihiko Yokohama, Yukihiro Kanai, Nanami Gotoh, Tetsuhiro Kasamatsu, Hiroshi Handa, Takayuki Saitoh, Hirokazu Murakami, Junko Hirato, Hayato Ikota, Norifumi Tsukamoto
Summary: Using targeted next-generation sequencing (NGS), this study found no significant genetic differences between Waldenstrom macroglobulinemia (WM) and non-IgM-type lymphoplasmacytic lymphoma (LPL). These findings suggest genetic similarities between these two subsets of LPL.
ACTA HAEMATOLOGICA
(2023)
Review
Hematology
Saurabh Zanwar, Jithma P. Abeykoon
Summary: WM is an indolent lymphoplasmacytic lymphoma, and genomic profiling helps identify novel therapeutic targets. Treatment selection takes into account the patient's genotype, preferences, comorbidities, and adverse effects. For fit patients with MYD88 (L) (265P) mutation, fixed duration chemoimmunotherapy may be preferred.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Hematology
Sabrin Tahri, Tarek H. Mouhieddine, Robert Redd, Luisa Lampe, Katarina Nilsson, Habib El-Khoury, Nang Kham Su, Amin H. Nassar, Elio Adib, Govind Bindra, Sarah Abou Alaiwi, Lorenzo Trippa, David P. Steensma, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Adam S. Sperling
Summary: Clonal hematopoiesis (CH) is associated with adverse outcomes in nonHodgkin lymphoma (NHL) and multiple myeloma patients undergoing autologous stem cell transplantation. However, its implications for patients with indolent NHL have not been well studied. This study reports the prevalence of CH in Waldenström macroglobulinemia (WM) patients and its association with clinical outcomes.
Article
Oncology
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V. Matous, David MacDonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango-Hisijara, Meletios A. Dimopoulos
Summary: The study demonstrates that single-agent ibrutinib continues to show sustained efficacy and tolerability in patients with heavily pretreated, rituximab-refractory Waldenstrom macroglobulinemia. The response rates deepened over time during the long-term treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramon Garcia-Sanz, David MacDonald, Veronique Leblond, Beatrice Mahe, Charles Herbaux, Jeffrey V. Matous, Constantine S. Tam, Leonard T. Heffner, Marzia Varettoni, M. Lia Palomba, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jerry Ping, Bernhard Hauns, Israel Arango-Hisijara, Meletios A. Dimopoulos
Summary: The final analysis of the iNNOVATE study demonstrated that ibrutinib-rituximab maintained sustained efficacy in patients with WM, regardless of MYD88 or CXCR4 mutation status, prior treatment, and key patient characteristics.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Morie A. Gertz
Summary: With the introduction of new effective therapeutic options, a structured approach to managing macroglobulinemia is needed. The authors conducted a review of treatment trials and provided therapeutic options based on the best available evidence.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Carly Leventoff, Timothy White, Catherine A. Flynn, Shayna Sarosiek, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Andrew R. Branagan, Elizabeth O'Donnell, Noopur Raje, Andrew J. Yee, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon
Summary: Ibrutinib monotherapy showed durable responses in treatment-naive patients with Waldenstrom macroglobulinemia, with CXCR4 mutations impacting VGPR attainment, time to major response, and 4-year PFS rate.
Article
Radiology, Nuclear Medicine & Medical Imaging
Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Fang Li
Summary: Ga-68-pentixafor PET/CT outperforms F-18-FDG PET/CT in response assessment of WM/LPL, showing different tumor responses and detecting disease progression more effectively.
CLINICAL NUCLEAR MEDICINE
(2021)
Article
Rheumatology
Sebastien Sanges, Lisa Rice, Ly Tu, Eleanor Valenzi, Jean-Luc Cracowski, David Montani, Julio C. Mantero, Camille Ternynck, Guillemette Marot, Andreea M. Bujor, Eric Hachulla, David Launay, Marc Humbert, Christophe Guignabert, Robert Lafyatis
Summary: This study examined the serum proteome of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and identified two proteins that were significantly correlated with pulmonary vascular resistance (PVR), potentially providing biomarkers for earlier diagnosis and treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Hematology
Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M. Totiger, David Coffey, Namrata Chandhok, Justin Watts, Luisa Cimmino, Sydney X. Lu, Niccolo Bolli, Kelly Bolton, Heather Landau, Jae H. Park, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey Tyner, Stephen Nimer, Elli Papaemmanuil, Saad Usmani, Gareth Morgan, Ola Landgren, Francesco Maura
Summary: Through genomic sequencing of 39 therapy-related myeloid malignancies, it was discovered that chemotherapy can accelerate the evolution of cancer cells by inducing mutations and DNA damage. Preleukemic clones (clonal hematopoiesis, CH) that exist before chemotherapy can acquire complex events and genomic drivers after chemotherapy, leading to the development of therapy-related myeloid neoplasms.
Letter
Hematology
Laure Goursaud, Celine Berthon, Bruno Quesnel
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Marion Perreard, Romane Florent, Jordane Divoux, Jean-Michel Grellard, Justine Lequesne, Melanie Briand, Benedicte Clarisse, Nathalie Rousseau, Esther Lebreton, Brice Dubois, Valentin Harter, Audrey Lasne-Cardon, Julien Drouet, Alisson Johnson, Anne-Laure Le Page, Celine Bazille, Corinne Jeanne, Martin Figeac, Nicolas Goardon, Dominique Vaur, Emmanuel Micault, Maxime Humbert, Juliette Thariat, Emmanuel Babin, Laurent Poulain, Louis-Bastien Weiswald, Vianney Bastit
Summary: This study aims to develop patient-derived tumor organoid (PDTO) models from Head and Neck Squamous Cell Carcinomas (HNSCC) in order to predict patients' response to treatment and evaluate innovative strategies. PDTO will be tested for sensitivity to chemotherapy, radiotherapy, and immunotherapy, and potential predictive biomarkers will be identified.
Editorial Material
Hematology
Sylvain Lamure, Charles Herbaux
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Guillaume Cartron, Emmanuel Bachy, Herve Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger
Summary: Rituximab improves progression-free survival and time to next treatment for patients with low-tumor burden follicular lymphoma. However, prolonged maintenance may raise concerns about resources use and patient adhesion. This study investigates the use of short rituximab maintenance using the subcutaneous route.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie-Jose Truong, Valerie Gregoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean-Pascal Meneboo, Sheherazade Sebda, Katia Bouchekioua-Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie-Christine Copin, David Tulasne, Alexis B. Cortot, Stephanie Kermorgant, Zoulika Kherrouche
Summary: Exon skipping mutations of the MET receptor tyrosine kinase (METex14) occur in a small percentage of non-small-cell lung cancer (NSCLC) and have been found to drive tumor growth and sensitivity to MET-tyrosine kinase inhibitors (TKIs). By using CRISPR/Cas9, researchers developed a METex14/WT isogenic model and demonstrated that the METex14 single alteration was sufficient to enhance cell survival and motility, as well as tumor formation, in vivo. They also found that human hepatocyte growth factor (hHGF) is required for the oncogenicity of METex14.
MOLECULAR ONCOLOGY
(2023)
Letter
Hematology
Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Jean Marc Schiano De Colella, Clement Bailly, Salim Kanoun, Stephanie Guidez, Emmanuel Gyan, Remy Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Herve Tilly, Roch Houot, F. Morschhauser, Guillaume Cartron, Charles Herbaux
Article
Hematology
Loic Vasseur, Laurene Fenwarth, Jerome Lambert, Stephane de Botton, Martin Figeac, Celine Villenet, Mael Heiblig, Pierre-Yves Dumas, Christian Recher, Celine Berthon, Emilie Lemasle, Delphine Lebon, Juliette Lambert, Christine Terre, Karine Celli-Lebras, Herve Dombret, Claude Preudhomme, Meyling Cheok, Raphael Itzykson, Nicolas Duployez
Summary: The expression of LSC17 gene is associated with risk stratification and measurable residual disease in AML patients, and high LSC17 expression is related to poor treatment response and shorter survival.
Article
Oncology
Jordane Divoux, Romane Florent, Margaux Jacobs, Justine Lequesne, Jean-Michel Grellard, Chankannira San, Sara Grossi, Katia Kerdja, Benedicte Clarisse, Gwenaelle Boudier, Francois Cherifi, Melanie Briand, Enora Dolivet, Alisson Johnson, Brice Dubois, Valentin Harter, Joelle Lacroix, Charlotte Raboutet, Brigitte Marie, Nathalie Rousseau, Cecile Blanc-Fournier, Dominique Vaur, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald, George Emile
Summary: This study aims to assess the feasibility of using patient-derived tumor organoids (PDTO) as predictive tools for evaluating the response of triple negative breast cancer (TNBC) patients to treatment. If PDTO can accurately predict patient response in a clinically relevant time frame, a prospective clinical trial could be designed to use PDTO to guide clinical decision-making. Additionally, this study will establish a living biobank of TNBC PDTO for future evaluation of innovative strategies.
Article
Oncology
Eileen M. Boyle, Patrick Blaney, James H. Stoeckle, Yubao Wang, Hussein Ghamlouch, Dylan Gagler, Marc Braunstein, Louis Williams, Avital Tenenbaum, Ariel Siegel, Xiaoyi Chen, Gaurav Varma, Jason Avigan, Alexander Li, Monica Jinsi, David Kaminetzsky, Arnaldo Arbini, Lydia Montes, Jill Corre, Even H. Rustad, Ola Landgren, Francesco Maura, Brian A. Walker, Michael Bauer, Benedetto Bruno, Aristotelis Tsirigos, Faith E. Davies, Gareth J. Morgan
Summary: This study identified various molecular variants of chr1 and revealed their impact on pathway utilization. Whole-arm gains of 1q were found to be associated with complex genetics, adverse prognosis, and multiple key drivers, providing potential therapeutic targets.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Marie Fernandes, Sonia Paget, Zoulika Kherrouche, Marie-Jose Truong, Audrey Vinchent, Jean-Pascal Meneboo, Sheherazade Sebda, Elisabeth Werkmeister, Clotilde Descarpentries, Martin Figeac, Alexis B. Cortot, David Tulasne
Summary: MET exon 14 skipping and MET Y1003F mutation both contribute to cell transformation in lung cancer by activating downstream signaling pathways and increasing cell mobility.
Article
Oncology
Lucie Thorel, Pierre-Marie Morice, Hippolyte Paysant, Romane Florent, Guillaume Babin, Cecilia Thomine, Marion Perreard, Edwige Abeilard, Florence Giffard, Emilie Brotin, Christophe Denoyelle, Celine Villenet, Sheherazade Sebda, Melanie Briand, Florence Joly, Enora Dolivet, Didier Goux, Cecile Blanc-Fournier, Corinne Jeanne, Marie Villedieu, Matthieu Meryet-Figuiere, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald
Summary: In the era of personalized medicine, establishing preclinical models that faithfully recapitulate original tumors is crucial for guiding clinical decisions. This study established 7 models derived from the same Ovarian Clear Cell Carcinoma, and comprehensively characterized their morphological, histological, and transcriptomic features, as well as their response to treatment. The results showed that the PDX and PDTO models derived from the patient tumor were able to recapitulate tumor heterogeneity and resistance to conventional treatments, making them potential tools for therapeutic decision support.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Genetics & Heredity
Gregory Lazarian, Bernard Leroy, Floriane Theves, Myriam Hormi, Remi Letestu, Virginie Eclache, Giulia Tueur, Adam Ameur, Audrey Bidet, Pascale Cornillet-Lefebvre, Frederic Davi, Eric Delabesse, Marie-Helene Estienne, Pascaline Etancelin, Olivier Kosmider, Sophy Laibe, Marc Muller, Nathalie Nadal, Dina Naguib, Cedric Pastoret, Stephanie Poulain, Pierre Sujobert, Lauren Veronese, Samia Imache, Valerie Lefebvre, Florence Cymbalista, Fanny Baran-Marszak, Thierry Soussi
Summary: TP53 aberrations are a major predictive factor for resistance to chemoimmunotherapy in CLL. This study analyzed 1,056 TP53 variants from 683 patients in France and compared them to a dataset of 5,173 TP53 variants from published articles. The analysis identified CLL-specific hotspot mutations and a novel splice variant. The study also found frequent copy-neutral loss of heterozygosity in CLL and the presence of multiple TP53 variants in a high proportion of patients.
Article
Immunology
Lea Fornero, Tarik Kanouni, Jean -Jacques Tudesq, Camille Pochard, Pauline Verot, Wendy Renier, Ludovic Gabellier, Guillaume Cartron, Philippe Guilpain, Charles Herbaux
Summary: The aim of this study is to evaluate the effectiveness of plasmapheresis initiated before or during rituximab treatment as prevention of cryoglobulinemic vasculitis flare. The results show that no flare occurred in the group receiving preventive plasmapheresis, while 5 flares occurred in the control group. Therefore, we believe that plasmapheresis is efficient and well tolerated to prevent rituximab-associated cryoglobulinemic vasculitis flare.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY
(2023)